Medine.co.uk

Out of date information, search another

Infacol

Out of date information, search another
Informations for option: Infacol, show other option

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

INFACOL

2    QUALITATIVE AND QUANTITATIVE COMPOSITION

Active ingredient:

Simeticone 40mg/ml

Excipients:

Methyl Hydroxybenzoate (E218) 0.18% w/v Propyl Hydroxybenzoate (E216) 0.02% w/v

For the full list of excipients, see section 6.1.

3.    PHARMACEUTICAL FORM

Oral suspension

4.    CLINICAL PARTICULARS

4.1.    Therapeutic Indications

An antiflatulent for the relief of griping pain, colic or wind due to swallowed air.

4.2. Posology and Method of Administration

For adults and elderly:

Not applicable.

For infants:

20mg (0.5ml) administered before each feed. If necessary this may be increased to 40mg (1ml).

Treatment with Infacol may provide a progressive improvement in symptoms over several days.

4.3. Contra-Indications

None stated.

4.4    Special warnings and precautions for use

The parahydrobenzoates used in infacol may cause delayed hypersensitivity reactions.

If symptoms persist, seek medical advice.

4.5    Interaction with other medicinal products and other forms of interaction

Levothyroxine may bind to simeticone. Absorption of levothyroxine may be impaired if Infacol is given concurrently to infants treated for thyroid disorders.

4.6.    Pregnancy and Lactation

Not applicable.

4.7.    Effects on Ability to Drive and Use Machines

Not applicable.

4.8.    Undesirable Effects

None stated.

4.9.    Overdose

In the event of deliberate or accidental overdosage, treat symptoms on appearance.

5. PHARMACOLOGICAL PROPERTIES

5.1. Pharmacodynamic Properties

Physiologically the active ingredient is a chemically inert, non-systemic gastric defoaming agent that works by altering the elasticity of interfaces of mucus-embedded bubbles in the gastrointestinal tract.

The gas bubbles are thus broken down or coalesced and in this form gas is more easily eliminated through eructation or passing flatus.

5.2. Pharmacokinetic Properties

Simeticone is not absorbed from the gastrointestinal tract.

5.3. Pre-clinical Safety Data

There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.

6. PHARMACEUTICAL PARTICULARS

6.1.    List of Excipients

Saccharin Sodium Hypromellose Orange flavour

Methyl Hydroxybenzoate (E218)

Propyl Hydroxybenzoate (E216)

Purified Water

6.2. Incompatibilities

None stated.

6.3 Shelf life

As packaged for sale : 3 years After first opening : 28 days.

6.4. Special Precautions for Storage

Store at room temperature (below 25°C).

6.5. Nature and Content of Container

High-density polyethylene bottle fitted with a low-density polyethylene dropper and evoprene teat containing 50ml, 75ml and 100ml of liquid.

6.6. Instructions for Use, Handling and Disposal

Not stated.

6.4 Marketing Authorisation Holder

Riverbridge House Anchor Boulevard Crossways Business Park Dartford Kent

DA2 6SL.

8. MARKETING AUTHORISATION NUMBER(S)

PL 0108/0100

9. DATE OF FIRST AUTHORISATION / RENEWAL OF AUTHORISATION

29th October 1986 / 20 January 1997

10 DATE OF REVISION OF THE TEXT

04/10/2013